Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.00
-3.1%		$4.72
$2.93
▼
$7.18
$502.05M1.492.18 million shs1.75 million shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-3.15%+5.82%-14.89%+8.70%-41.52%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.00
-3.1%		$4.72
$2.93
▼
$7.18
$502.05M1.492.18 million shs1.75 million shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-3.15%+5.82%-14.89%+8.70%-41.52%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
2.60
Moderate Buy$8.60115.00% Upside
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OASM, AQST, and ASLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$10.00
10/15/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/10/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$11.00
8/24/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$10.00
(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$44.54M11.27N/AN/A($0.28) per share-14.29
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
OASM
Oasmia Pharmaceutical AB (publ)
$220K0.00N/AN/A$0.63 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$83.78M-$0.65N/AN/AN/A-144.63%N/A-52.40%11/4/2026 (Estimated)
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/AN/AN/AN/A-8,633.64%-43.94%-28.92%N/A

Latest OASM, AQST, and ASLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.10N/AN/AN/A$11.02 millionN/A
8/11/2026Q2 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.1050-$0.18-$0.0750-$0.18$11.42 million$13.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
7.19
6.74
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
OASM
Oasmia Pharmaceutical AB (publ)
0.11%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
6.81%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
OASM
Oasmia Pharmaceutical AB (publ)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
147125.51 million116.97 millionOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable

Recent News About These Companies

Double Bond Pharmaceutical International AB (DBPHAb)
October 31, 2024  |  investing.comhttps://www.investing.com/equities/double-bond-pharmaceutical-intl-income-statement
Sector-Health Care & Pharmaceuticals
May 17, 2024  |  newsweek.comN
BOEUF Bonesupport Holding AB (publ)
April 30, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/BOEUF
Resurs Holding AB (publ) (RESURS.ST)
February 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RESURS.ST/
QuiaPEG Pharmaceuticals Holding AB QUIA
January 6, 2024  |  morningstar.comM
Newbury Pharmaceuticals AB (NEWBRY)
November 29, 2023  |  investing.comhttps://www.investing.com/equities/newbury-pharmaceuticals-ab
Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme
September 26, 2023  |  bestmediainfo.comB
Lipigon Pharmaceuticals AB (LPGO)
September 14, 2023  |  investing.comhttps://www.investing.com/equities/lipigon-pharmaceuticals-ab
Speqta publ AB (SPEQT)
August 25, 2023  |  investing.comhttps://www.investing.com/equities/203-web-group-publ-ab
PRXXF Paradox Interactive AB (publ)
August 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/PRXXF
Notice of annual general meeting in Alzinova AB (publ)
April 25, 2023  |  privataaffarer.seP
Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ)
April 21, 2023  |  privataaffarer.seP
Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)
April 2, 2023  |  europapress.esE
OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M
February 26, 2023  |  seekingalpha.comhttps://seekingalpha.com/news/3940679-oxe-marine-ab-publ-non-gaap-eps-of-sek043-revenue-of-sek322m
US regulators clear way for more monkeypox vaccine shipments
July 14, 2022  |  starherald.comS
PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)
March 24, 2022  |  avanza.seA
Oasmia expands R&D ability with planned laboratory upgrade
March 17, 2022  |  privataaffarer.seP
Orexo appoints Fredrik Järrsten as new CFO
March 11, 2022  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2022/03/11/orexo-appoints-fredrik-j-xe4-rrsten-as-new-cfo
Notice of extra general meeting in Terranet AB
November 29, 2021  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2021-11/54612185-notice-of-extra-general-meeting-in-terranet-ab-399.htm
Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth | robust CAGR of 7.7% over the forecast period (2017 – 2025).
September 17, 2021  |  medgadget.comhttps://www.medgadget.com/2021/09/pet-cancer-therapeutics-market-know-how-industry-to-experience-positive-growth-robust-cagr-of-7-7-over-the-forecast-period-2017-2025.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.00 -0.13 (-3.15%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$4.03 +0.03 (+0.72%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 10/23/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas